Researchers Advance Closer to Developing HIV Vaccine
Insight into the inner complexities of HIV and cytotoxic T lymphocyte evolution raise hopes for HIV cure.
In a new study, researchers found that a single T cell-selected HIV mutation is able to produce different T cell adaptations.
A study published in Cell Reports sought to increase the understanding of HIV and cytotoxic T lymphocyte (CTL) co-evolution, and to improve the development of T cell-mediated AIDS vaccines, which induce the development of HIV-specific T cells within the body. For the study, researchers primarily focused on a mutation frequently found in individuals who have the
It’s estimated that approximately 70% of the Japanese population have this mutation. The results of the study found that 1 mutation produced 2 outcomes.
During the HIV/CTL coevolution, the mutation induced a new T cell repertoire in 1 RF10 mutant epitope, but not in the RW8 mutant epitope. The coadaptation was clarified between a single HIV-1 mutation and T cells.
“This study demonstrated that only a single mutation selected by T cells produced 2 different outcomes in T cell adaptation suggesting a more complex co-evolution between HIV and T cell in the body,” said lead researcher Masafumi Takiguchi. “This finding will contribute to the development of an effective T cell-mediated AIDS vaccine in the future.”
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025